Integra LifeSciences (NASDAQ:IART) Given New $35.00 Price Target at JMP Securities

Integra LifeSciences (NASDAQ:IART) had its target price cut by JMP Securities from $40.00 to $35.00 in a research report released on Tuesday, Benzinga reports. They currently have a market outperform rating on the life sciences company’s stock.

Several other research firms have also recently weighed in on IART. Citigroup cut shares of Integra LifeSciences from a neutral rating to a sell rating and lowered their price target for the company from $30.00 to $23.00 in a report on Tuesday. Truist Financial cut their target price on shares of Integra LifeSciences from $32.00 to $26.00 and set a hold rating on the stock in a research report on Tuesday. Oppenheimer lowered shares of Integra LifeSciences from an outperform rating to a market perform rating in a research report on Tuesday, May 7th. Bank of America dropped their price target on shares of Integra LifeSciences from $42.00 to $26.00 and set an underperform rating for the company in a research note on Tuesday, May 7th. Finally, Morgan Stanley lifted their target price on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an underweight rating in a research note on Monday, July 15th. Four research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of Hold and an average target price of $29.25.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock opened at $24.61 on Tuesday. Integra LifeSciences has a 52 week low of $22.36 and a 52 week high of $45.65. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of 49.22, a PEG ratio of 0.84 and a beta of 1.11. The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 3.39. The firm has a fifty day moving average of $29.53 and a two-hundred day moving average of $33.40.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.01. The company had revenue of $418.20 million during the quarter, compared to the consensus estimate of $413.07 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The company’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.71 EPS. As a group, equities research analysts predict that Integra LifeSciences will post 2.47 EPS for the current year.

Insider Activity

In other Integra LifeSciences news, Chairman Stuart Essig purchased 52,641 shares of the company’s stock in a transaction that occurred on Thursday, May 23rd. The shares were bought at an average cost of $28.49 per share, for a total transaction of $1,499,742.09. Following the purchase, the chairman now owns 487,922 shares of the company’s stock, valued at approximately $13,900,897.78. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 3.10% of the company’s stock.

Institutional Trading of Integra LifeSciences

Several institutional investors and hedge funds have recently bought and sold shares of the company. Capital Research Global Investors grew its holdings in shares of Integra LifeSciences by 37.7% during the 1st quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock valued at $209,828,000 after purchasing an additional 1,621,655 shares during the last quarter. Madison Avenue Partners LP increased its position in shares of Integra LifeSciences by 8.0% during the fourth quarter. Madison Avenue Partners LP now owns 1,042,156 shares of the life sciences company’s stock valued at $45,386,000 after buying an additional 77,489 shares during the period. Leeward Investments LLC MA grew its holdings in Integra LifeSciences by 17.8% in the first quarter. Leeward Investments LLC MA now owns 452,438 shares of the life sciences company’s stock worth $16,039,000 after purchasing an additional 68,247 shares during the period. Dimensional Fund Advisors LP grew its holdings in Integra LifeSciences by 4.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,615,112 shares of the life sciences company’s stock worth $70,340,000 after purchasing an additional 63,323 shares during the period. Finally, Cooke & Bieler LP grew its holdings in shares of Integra LifeSciences by 4.4% during the fourth quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock valued at $123,447,000 after buying an additional 120,410 shares during the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.